SCHEMBL2035615

SCHEMBL2035615

O=[C]CCCC(=O)c1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.67
MAPT P10636 3/20 0.67
L3MBTL1 Q9Y468 2/20 0.67
LMNA P02545 2/20 0.67
HDAC1 Q13547 5/20 0.60
HDAC8 Q9BY41 5/20 0.60
HDAC3 O15379 1/20 0.60
HDAC4 P56524 1/20 0.60
HDAC7 Q8WUI4 1/20 0.60
HDAC2 Q92769 1/20 0.60
HDAC10 Q969S8 1/20 0.60
HDAC11 Q96DB2 1/20 0.60
HDAC6 Q9UBN7 1/20 0.60
HDAC9 Q9UKV0 1/20 0.60
HDAC5 Q9UQL6 1/20 0.60
NPC1 O15118 1/20 0.58
CASP3 P42574 1/20 0.58
RAB9A P51151 1/20 0.58
SENP8 Q96LD8 1/20 0.58
SENP7 Q9BQF6 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12989353 0.92 TDP1 (0.74) TDP1MAPTL3MBTL1LMNAHDAC1
SCHEMBL2240191 0.92 TDP1 (0.74) TDP1MAPTL3MBTL1LMNAHDAC1
SCHEMBL8153235 0.92 TDP1 (0.74) TDP1MAPTL3MBTL1LMNAHDAC1
SCHEMBL10457866 0.92 TDP1 (0.74) TDP1MAPTL3MBTL1LMNAHDAC1
SCHEMBL276675 0.88 TDP1 (0.59) TDP1MAPTL3MBTL1LMNAHDAC1
SCHEMBL7068671 0.83 TDP1 (0.95) TDP1MAPTL3MBTL1LMNAHDAC1
SCHEMBL1052631 0.83 TDP1 (0.86) TDP1MAPTL3MBTL1LMNAHDAC1
SCHEMBL10598379 0.82 TDP1 (0.64) TDP1MAPTL3MBTL1LMNAHDAC1
SCHEMBL9185068 0.82 TDP1 (0.64) TDP1MAPTL3MBTL1LMNAHDAC1
SCHEMBL28253977 0.81 NPC1 (0.71) L3MBTL1NPC1RAB9AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120329711-A1 GLP-1 RECEPTOR AGONIST COMPOUNDS WITH A MODIFIED N-TERMINUS NORDISK A/S (DK) 2012-12-27 US claimed
EP-0001616-A2 Curable epoxy resin compositions CIBA-GEIGY AG (CH) 1979-05-02 EP claimed
US-20120329711-A1 GLP-1 RECEPTOR AGONIST COMPOUNDS WITH A MODIFIED N-TERMINUS NORDISK A/S (DK) 2012-12-27 US disclosed
EP-2512518-A1 GLP-1 RECEPTOR AGONIST COMPOUNDS WITH A MODIFIED N-TERMINUS Novo Nordisk A/S (DK) 2012-10-24 EP disclosed
WO-2011073328-A1 GLP-1 RECEPTOR AGONIST COMPOUNDS WITH A MODIFIED N-TERMINUS NOVO NORDISK A/S (DK) 2011-06-23 WO disclosed
EP-0901787-B1 Stabilized pharmaceutical composition TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2003-05-28 EP disclosed
US-4259236-A COLORFAST RED SHADES ON POLYESTERS CIBA-GEIGY CORPORATION (US) 1981-03-31 US disclosed
US-4101541-A DYES FOR POLYESTERS OR POLYPROPYLENE CIBA-GEIGY CORPORATION (US) 1978-07-18 US disclosed
US-3998805-A MONOAZO DYES; POLYESTERS; YELLOW, RED, OR ORANGE SHADES CIBA-GEIGY CORPORATION (US) 1976-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329711-A1 GLP-1 RECEPTOR AGONIST COMPOUNDS WITH A MODIFIED N-TERMINUS GLP1R, GIPR, GCGR TDP1 4293/4885MAPT 3924/4885L3MBTL1 1171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.